Fortrea Holdings (FRA:K67) Common Stock : €0 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Common Stock?

Fortrea Holdings's quarterly common stock declined from Sep. 2023 (€0 Mil) to Dec. 2023 (€0 Mil) but then stayed the same from Dec. 2023 (€0 Mil) to Mar. 2024 (€0 Mil).

Fortrea Holdings's annual common stock stayed the same from Dec. 2021 (€0 Mil) to Dec. 2022 (€0 Mil) but then increased from Dec. 2022 (€0 Mil) to Dec. 2023 (€0 Mil).

Fortrea Holdings Common Stock Historical Data

The historical data trend for Fortrea Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Common Stock Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

0.09

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial						0.09	0.09	0.09	0.09	0.09

Fortrea Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Fortrea Holdings (FRA:K67) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

FTRE:USA

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings (FRA:K67) Headlines

No Headlines